Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Dec 5;144(23):2456-2461.
doi: 10.1182/blood.2024024962.

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie  1   2 , Jenna Fernandez  1 , Terra Lasho  1 , Christy Finke  1 , Michelle Amundson  1 , Kristen B McCullough  1 , Betsy R LaPlant  1 , Abhishek A Mangaonkar  1 , Naseema Gangat  1 , Kaaren K Reichard  3 , Michelle Elliott  1 , Thomas E Witzig  1 , Mrinal M Patnaik  1
Affiliations
Clinical Trial

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie et al. Blood. .

Abstract

This phase 2 trial assessed high-dose IV ascorbic acid in TET2 mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.clinicaltrials.gov as #NCT03418038.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: N.G. served on the advisory boards for Disc Medicine and Agios. M.M.P. has received research funding from Kura Oncology, Epigenetix, Polaris, Solu Therapeutics, and Stemline Therapeutics. The remaining authors declare no competing financial interests.

References

    1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. - PMC - PubMed
    1. Weeks L, Niroula A, Neuberg DS, et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2022;140(suppl 1):2229–2231. - PMC - PubMed
    1. Xie Z, Komrokji RS, Al-Ali N, et al. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024;144(19):2033–2044. - PMC - PubMed
    1. Li M, Binder M, Lasho T, et al. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021;5(8):2272–2278. - PMC - PubMed
    1. Xie Z, Nanaa A, Saliba A, et al. Treatment outcome for symptomatic patients with clonal cytopenia of undetermined significance: a single-institution retrospective study [abstract] Blood Cancer J. 2021;11(3):43. - PMC - PubMed

Publication types

Associated data